ARD: Baricitinib in recurrent giant cell arteritis: a 52-week prospective open-label pilot study

Objective : Giant cell arteritis ( GCA) is a chronic rheumatic disease with a high recurrence rate during glucocorticoid taperi.

Objectives : Giant cell arteritis ( GCA ) is a chronic rheumatic disease with a high recurrence rate during glucocorticoid taperin.

Methods We conducted a prospective, open-label pilot study of baricitinib ( 4 mg/ day) with graded glucocorticoids ( GC ) and accelerated tapering in patients with recurrent GC.

Results in group 15

patients ( 11 , 73% female), mean age at enrollment was 74 ( SD 2 ) years, median duration of GCA was 9 ( IQR 7-21 ) months, and median previous recurrence was 1 ( 1 -2 ) time.

patients ( 11 , 73% female), mean age at enrollment was 74 ( SD 2 ) years, median duration of GCA was 9 ( IQR 7-21 ) months, and median previous recurrence was 1 ( 1 -2 ) time.

Conclusions In this proof-of-concept study, baricitinib 4 mg/ day was well tolerated and GC discontinuation was allowed in most patients with recurrent GC.

Source: Koster MJ, Crowson CS, Giblon RE , et a.
Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot stu.
Annals of the Rheumatic Diseases2022;81:861-86 , et al Annals of the Rheumatic Diseasesleave a message here